A year after INC Research's $150 million IPO, the company's longtime financial supporters are flipping more shares in exchange for $272 million, taking a page from the private equity giants that have profited from the trend of CROs going public.
INC Research is ticking up its revenue expectations for 2015 after turning in another quarter of sales growth, counting on its expanded operation to keep contracts rolling in.
INC Research added a new tool for early-stage safety studies, bringing in a new technology the company says will make Phase I cardiac trials more efficient.
Leading CRO INC Research is boosting its upper echelon in the areas of general medicine and central nervous system R&D, promoting two key members.
Thanks to pharma's R&D cost-cutting efforts, the CRO industry will expand at nearly a 10% clip through 2019, a new report says, citing trends that many industry-watchers will find familiar.
The deep-pocketed outfits that helped take INC Research public last year are angling to cash in on the CRO's resulting success on the market, flipping shares in a secondary offering.
CRO INC Research posted another quarter of double-digit revenue growth, lifting its 2015 guidance for the second time to account for a jump in new business.
INC Research has started what it says is the industry's first site advocacy group, gathering study investigators to discuss how to improve speed and results in R&D.
CRO INC Research boosted its sales by 14.5% in the first quarter, returning to profitability as it blueprints a big year.
Months removed from a $150 million IPO, INC Research is looking to raise its profile among the world's largest CROs, inching toward the $1 billion annual revenue mark in the new year.